TY - JOUR
T1 - Drug Delivery to the Brain across the Blood–Brain Barrier Using Nanomaterials
AU - Tsou, Yung Hao
AU - Zhang, Xue Qing
AU - Zhu, He
AU - Syed, Sahla
AU - Xu, Xiaoyang
N1 - Funding Information:
Y.-H.T. and X.-Q.Z. contributed equally to this work. The financial support from New Jersey Institute of Technology (NJIT) startup funding, New Jersey Health Foundation (PC102-17), and NSF Innovation Corps (1723667) program is gratefully acknowledged.
Publisher Copyright:
© 2017 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim
PY - 2017/11/20
Y1 - 2017/11/20
N2 - A major obstacle facing brain diseases such as Alzheimer's disease, multiple sclerosis, brain tumors, and strokes is the blood–brain barrier (BBB). The BBB prevents the passage of certain molecules and pathogens from the circulatory system into the brain. Therefore, it is nearly impossible for therapeutic drugs to target the diseased cells without the assistance of carriers. Nanotechnology is an area of growing public interest; nanocarriers, such as polymer-based, lipid-based, and inorganic-based nanoparticles can be engineered in different sizes, shapes, and surface charges, and they can be modified with functional groups to enhance their penetration and targeting capabilities. Hence, understanding the interaction between nanomaterials and the BBB is crucial. In this Review, the components and properties of the BBB are revisited and the types of nanocarriers that are most commonly used for brain drug delivery are discussed. The properties of the nanocarriers and the factors that affect drug delivery across the BBB are elaborated upon in this review. Additionally, the most recent developments of nanoformulations and nonconventional drug delivery strategies are highlighted. Finally, challenges and considerations for the development of brain targeting nanomedicines are discussed. The overall objective is to broaden the understanding of the design and to develop nanomedicines for the treatment of brain diseases.
AB - A major obstacle facing brain diseases such as Alzheimer's disease, multiple sclerosis, brain tumors, and strokes is the blood–brain barrier (BBB). The BBB prevents the passage of certain molecules and pathogens from the circulatory system into the brain. Therefore, it is nearly impossible for therapeutic drugs to target the diseased cells without the assistance of carriers. Nanotechnology is an area of growing public interest; nanocarriers, such as polymer-based, lipid-based, and inorganic-based nanoparticles can be engineered in different sizes, shapes, and surface charges, and they can be modified with functional groups to enhance their penetration and targeting capabilities. Hence, understanding the interaction between nanomaterials and the BBB is crucial. In this Review, the components and properties of the BBB are revisited and the types of nanocarriers that are most commonly used for brain drug delivery are discussed. The properties of the nanocarriers and the factors that affect drug delivery across the BBB are elaborated upon in this review. Additionally, the most recent developments of nanoformulations and nonconventional drug delivery strategies are highlighted. Finally, challenges and considerations for the development of brain targeting nanomedicines are discussed. The overall objective is to broaden the understanding of the design and to develop nanomedicines for the treatment of brain diseases.
KW - blood brain barrier
KW - drug delivery
KW - nanotechnology
UR - http://www.scopus.com/inward/record.url?scp=85031411532&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85031411532&partnerID=8YFLogxK
U2 - 10.1002/smll.201701921
DO - 10.1002/smll.201701921
M3 - Review article
C2 - 29045030
AN - SCOPUS:85031411532
SN - 1613-6810
VL - 13
JO - Small
JF - Small
IS - 43
M1 - 1701921
ER -